http://jnnp.bmjjournals.com/cgi/content/abstract/71/1/107
J Neurol Neurosurg Psychiatry 2001;71:107-110 ( July )
F Bandinia, E Castellob, L Mazzellaa,
G L Mancardia, C Solaroa
a Department of Neurological Sciences
and Vision, University of Genoa, via De Toni 5, 16132 Genoa, Italy, b ENT
Division, Head and Neck Department, S Martino Hospital, Genoa, Italy
Correspondence to: Dr F Bandini fbandini@neurologia.unige.it
Received 15 November 2000 and in
revised form 16 February 2001; Accepted 23 February 2001
Acquired nystagmus occurs frequently
in patients with multiple sclerosis and is often the cause of illusory
motion of the environment (oscillopsia), and blurring of vision.
Based primarily on the beneficial
effect of gabapentin on acquired pendular nystagmus (APN), a GABAergic
mechanism in controlling nystagmus has been hypothesised.
If increasing GABA concentrations
in the CNS are critical for the treatment of nystagmus, then a selective
GABAergic drug should be highly successful.
However, as gabapentin is not a selective
GABAergic agent, vigabatrin, a "pure" GABAergic medication, and gabapentin,
were compared in a single blind cross over trial in eight patients with
definite multiple sclerosis.
Patients were randomly assigned to
begin with gabapentin (1200 mg daily) or vigabatrin (2000 mg daily). Neuro-ophthalmological
and electro-oculographic (EOG) evaluations were performed four and three
times, respectively.
Treatment efficacy was based on improving
visual acuity and EOG indices (amplitude or frequency of nystagmus, or
both) by at least 50% of pretreatment values.
Three out of eight patients dropped
out due to adverse effects.
In the remaining five patients gabapentin
improved symptomatic pendular or gaze evoked jerk nystagmus in four.
Three patients decided to continue
gabapentin therapy. Importantly, vigabatrin proved useful in only one out
of five patients, suggesting that gabapentin effectiveness may be related
to additional non-GABAergic mechanisms of action.
Interaction with cerebral glutamate
transmission by inhibition of NMDA receptor might be an alternative hypothesis
for the therapeutic action of gabapentin.